Researchers analyzing respiratory syncytial virus (RSV) samples from adults in Georgia during 2024-2025 found multiple co-circulating virus variants, with minimal evidence that vaccines are driving the evolution of escape mutations. The study, published in the CDC's Emerging Infectious Diseases journal, examined genome sequences from 182 adults and identified diverse RSV strains circulating in the population, even as vaccination rates remain low among eligible adults.

What Is RSV and Why Should Adults Care?

Respiratory syncytial virus is a common respiratory infection that most people recover from without serious complications. However, RSV poses real risks for older adults, infants, and people with weakened immune systems. In the United States, RSV vaccines became available for adults based on age and underlying health conditions starting in 2024. Despite this, uptake has been modest. Among the 96 adults in the Georgia study who were eligible for vaccination based on age (75 years or older) or age 50-74 with chronic conditions, only 17 people, or 18%, had actually received the vaccine.

The study participants reported typical RSV symptoms, including cough (93%), fever (31%), and shortness of breath (25%). More concerning, 13% required hospitalization, 2% needed intensive care, and 3% died from their infection. These outcomes highlight why vaccination matters for vulnerable populations.

Are RSV Vaccines Creating New Resistant Variants?

One major concern when rolling out new vaccines is whether the virus will evolve to escape immune protection. This has happened with some viruses in the past. Researchers specifically looked for mutations in the RSV fusion protein, the target of current vaccines, to see if vaccinated individuals were harboring variants that might resist vaccine protection.

The findings were reassuring. Among 125 virus sequences with high-quality genetic data, researchers identified 25 mutations in the fusion protein's antigenic sites, which are the regions vaccines target. However, only one mutation appeared unique to vaccinated people, and it occurred in just a single virus sample. Another mutation, called S377N, appeared more frequently in vaccinated individuals (43%) compared to unvaccinated people (5%), but its actual effect on vaccine effectiveness remains unknown.

Most other mutations occurred at the same or higher frequency in unvaccinated compared to vaccinated people, suggesting they are not being selected for by vaccine pressure. This is important because it means the virus is not yet adapting specifically to evade vaccine-induced immunity.

What Virus Variants Are Currently Circulating?

The Georgia study revealed a complex landscape of RSV diversity. Researchers detected similar numbers of RSV-A and RSV-B subtypes, the two main groups of RSV. Within RSV-A, the dominant variant was lineage A.D.3.1, accounting for 29% of samples, followed by A.D.5.2 at 15% and A.D.1.5 at 10%. For RSV-B, lineage B.D.E.1 dominated at 58% of samples.

Importantly, the virus sequences from vaccinated and unvaccinated individuals did not cluster separately on genetic trees, meaning the vaccines were not selecting for distinct viral populations. The researchers noted that several mutations, such as I59V and K470R in RSV-A, occurred at higher frequencies than previously reported in earlier studies, suggesting ongoing natural drift in the virus.

How to Stay Informed About RSV Surveillance and Vaccine Updates

• Check CDC Recommendations Regularly: The CDC updates RSV vaccination guidance annually based on new data. Adults 60 and older, especially those with chronic conditions like heart disease, lung disease, or diabetes, should review current recommendations with their healthcare provider.
• Monitor Genomic Surveillance Reports: The CDC and academic institutions like Emory University publish regular updates on circulating RSV variants. These reports help public health officials detect any emerging mutations that might affect vaccine performance.
• Report Breakthrough Infections: If you are vaccinated and still develop RSV, reporting this to your healthcare provider helps researchers understand real-world vaccine effectiveness and track any patterns in variant emergence.

What Does This Mean for Future RSV Vaccine Strategy?

The study's authors emphasized the importance of continued surveillance. "Continued large-scale RSV genomic surveillance will be critical for detecting emerging immune-escape variants and understanding viral evolution in the postvaccine era," they noted in their analysis. This means researchers will keep monitoring RSV strains as more people get vaccinated, watching for any signs that the virus is adapting.

One limitation of the current study is the small number of vaccinated individuals available for analysis. With only 17 vaccinated people in the cohort, researchers could not perform detailed statistical comparisons. As vaccination rates increase and more vaccinated people are sequenced, a clearer picture of whether vaccine-driven evolution is occurring will emerge.

The findings also highlight a broader public health challenge: low vaccine uptake. With only 47.5% of adults over 75 years old and 38.1% of adults aged 60-74 with high-risk conditions receiving RSV vaccines nationally, the virus continues to circulate widely in vulnerable populations. Higher vaccination rates could reduce transmission and potentially slow any future viral evolution.

For now, the good news is that RSV vaccines appear to be working without triggering widespread vaccine-resistant variants. However, the ongoing natural evolution of the virus, reflected in new mutations appearing in both vaccinated and unvaccinated people, underscores why genomic surveillance must continue. As RSV vaccines become more widely used, researchers will need to monitor whether the virus adapts in ways that could eventually reduce vaccine effectiveness.